Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) FCF Margin (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed FCF Margin for 5 consecutive years, with 26435.23% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 3479420.0% year-over-year to 26435.23%, compared with a TTM value of 18604.82% through Dec 2025, up 2122347.0%, and an annual FY2024 reading of 2618.65%, down 148794.0% over the prior year.
  • FCF Margin was 26435.23% for Q4 2025 at SAB Biotherapeutics, down from 30144.19% in the prior quarter.
  • Across five years, FCF Margin topped out at 30144.19% in Q3 2025 and bottomed at 8358.96% in Q4 2024.
  • Average FCF Margin over 5 years is 2895.52%, with a median of 79.69% recorded in 2022.
  • The sharpest move saw FCF Margin crashed -567563bps in 2023, then skyrocketed 3479420bps in 2025.
  • Year by year, FCF Margin stood at 65.47% in 2021, then dropped by -18bps to 77.41% in 2022, then crashed by -5624bps to 4430.85% in 2023, then crashed by -89bps to 8358.96% in 2024, then surged by 416bps to 26435.23% in 2025.
  • Business Quant data shows FCF Margin for SABS at 26435.23% in Q4 2025, 30144.19% in Q3 2025, and 11114.37% in Q2 2025.